Andrzej Hellmann

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Jan A. Burger, Alessandra Tedeschi, Paul M. Barr et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Thomas J. Kipps, Stephan Stilgenbauer et al. · Journal of Clinical Oncology · 2010 · 587 citations

Pharmacy, Oncology, Pharmacotherapy +17

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 489 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial

Martin Tauschmann, Hood Thabit, Lia Bally et al. · The Lancet · 2018 · 437 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Bertrand Coiffier, Stéphane Leprêtre, Lars Møller Pedersen et al. · Blood · 2007 · 385 citations

Medicine, Hematology, Oncology +16